Compare Crispr Therapeutics AG (CRSP) vs Levi Strauss & Co. (LEVI) Price & Performance

CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.

The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.

Levi Strauss (LEVI) trades at $19.51, down 4.97% on the day, with a bearish technical signal despite strong fundamentals. The company demonstrates robust profitability with 62.81% gross margins and 8.83% net income margin, supported by four consecutive quarterly earnings beats. Analyst consensus remains strongly bullish with a $29 price target representing 49% upside potential. Recent developments include the appointment of a new CFO and continued momentum in denim demand driving revenue growth.

The stock presents a compelling value opportunity with attractive valuation multiples (P/E 12.53, P/S 1.12) and strong cash flow generation. However, near-term technical weakness and recent cybersecurity concerns require monitoring. The company's direct-to-consumer strategy and international expansion provide growth catalysts, though execution risks and market volatility remain considerations for investors.